Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Biotechnology company Bacilligen has reported the receipt of a small business innovation research grant from the National Cancer Institute, a component of the US National Institutes of Health, to develop improved therapy for bladder cancer.
Subscribe to our email newsletter
The project, entitled improved bladder cancer therapy with recombinant BCG, aims to improve the safety and efficacy of an existing immunotherapy, BCG, that can have difficult side effects that prevent some patients from successfully utilizing the treatment.
Some patients do not respond to BCG at all. Bacilligen’s product will exhibit increased potency and reduced side effects in patients thus permitting more patients to complete their treatment course and improve the treatment success rate.
Steve Bende, president and CEO of Bacilligen, said: “Bacilligen is proud that National Cancer Institute (NCI) finds merit in our bladder cancer program. We look forward to successful completion of the work and bringing this improved product to the clinic as soon as possible.”